| 1.16 0.1 (9.43%) | 07-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.67 |
1-year : | 1.95 |
| Resists | First : | 1.42 |
Second : | 1.67 |
| Pivot price | 1.18  |
|||
| Supports | First : | 1.08 |
Second : | 0.87 |
| MAs | MA(5) : | 1.06 |
MA(20) : | 1.2 |
| MA(100) : | 1.28 |
MA(250) : | 1.36 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 47.5 |
D(3) : | 32.7 |
| RSI | RSI(14): 47.3 |
|||
| 52-week | High : | 2.31 | Low : | 0.87 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TELO ] has closed above bottom band by 44.3%. Bollinger Bands are 83.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.24 - 1.25 | 1.25 - 1.25 |
| Low: | 1.04 - 1.04 | 1.04 - 1.05 |
| Close: | 1.15 - 1.16 | 1.16 - 1.17 |
Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against various age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, and also to assist in recovery post-chemotherapy. It achieves this by disrupting and inhibiting inflammatory pathways that are triggered by interleukin-17. Established in 2021, the company was initially known as Metallo Therapies Inc., officially adopting the name Telomir Pharmaceuticals, Inc. on October 10, 2022. The company's headquarters are located in Baltimore, Maryland.
Mon, 15 Jun 2026
Telomir (NASDAQ: TELO) adds Telomir-Zn diabetes data to support FDA-cleared TNBC trial - Stock Titan
Wed, 20 May 2026
Study links Telomir-Zn to better survival in toxic copper buildup disorder - Stock Titan
Fri, 24 Apr 2026
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn) - ACCESS Newswire
Fri, 24 Apr 2026
Telomir completes acquisition of TELI Pharmaceuticals - Investing.com
Thu, 28 Aug 2025
Breakthrough in Telomir Pharmaceuticals’ Drug Research Sparks Market Optimism - timothysykes.com
Thu, 24 Apr 2025
Telomir Pharms (TELO) Stock Price, News & Analysis - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 69 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 35 (%) |
| Held by Institutions | 3.2 (%) |
| Shares Short | 953 (K) |
| Shares Short P.Month | 923 (K) |
| EPS | -0.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.14 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -187 % |
| Return on Equity (ttm) | -384.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -4.15 |
| PEG Ratio | 0 |
| Price to Book value | 8.28 |
| Price to Sales | 0 |
| Price to Cash Flow | -17.35 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|